 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|||||||||||||
|
[ back to News ]
|
|||||||||||||||
Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity Platform). U.S. Patents 7,855,204 and 7,820,666 specifically claim deuterium analogs of gefitinib and sitaglipin. In addition, Concert has over 90 issued or pending US and European patents on deuterated drug families.
“Selective deuterium modification can improve important drug properties, enabling us to obtain strong intellectual property protection for our novel compositions of matter in the US and abroad." said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.
About Deuterium
Deuterium is a safe, non-radioactive relative of hydrogen that can be isolated from sea water and has been used extensively in human metabolic and clinical studies. Since deuterium resembles hydrogen, deuterium-containing compounds are expected to preserve the pharmacological activity of their hydrogen analogs. An important difference is that deuterium is heavier than hydrogen and therefore forms a stronger chemical bond to a carbon atom of a drug. The stronger chemical bond obtained by selective deuterium modification in select instances may substantially improve the drug’s metabolic properties, potentially resulting in better safety, tolerability and/or efficacy.
About Concert
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease, renal disease and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals, the CoNCERT logo and DCE Platform are trademarks of Concert Pharmaceuticals, Inc.
[ back to top ]
|
|
|
|
|
| ©2009 Concert Pharmaceuticals, Inc. Design by Digizyme |
||||
|
|
|
|
|